Idogen AB (publ) announced that the first patient has been included in the Phase I/IIa clinical trial with ItolDC-028, the company's cell therapy that is part of its IDO 8 program. The patient was included at Oslo University Hospital, where the trial will be carried out under the management of professor and chief physician Pål Andre Holme. The patients that will be included in the study all have hemophilia A and should have developed antibodies to their treatment with factor VIII.

They should also have undergone unsuccessful immune tolerance induction (ITI) treatment and still have inhibitors against factor VIII. The patient who has been enrolled in Norway will now undergo planned tests ahead of the apheresis process, the purpose of which is to collect the patient's white blood cells which are then used to manufacture the cell therapy. The white blood cells will be sent to the company's partner, Radboud University Medical Center (RUMC) in the Netherlands, where they will be processed using the company's patented technology.

The overall objective of the therapy is toinduce a tolerance to factor VIII, which in turn means the patient can once again undergo factor VIII treatment without any problems.